Search results
Showing 1 to 15 of 53 results for rheumatology
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
In development Reference number: GID-TA11330 Expected publication date: 21 May 2026
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]
In development Reference number: GID-TA11478 Expected publication date: 11 March 2026
In development Reference number: GID-TA11733 Expected publication date: 26 August 2026
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446
In development Reference number: GID-TA11552 Expected publication date: 09 September 2026
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members